Shop

Simulect 20 mg Injection (Basiliximab) is a monoclonal antibody used to prevent acute organ rejection in kidney transplant recipients. Administered intravenously around the time of transplant, it targets the CD25 receptor on activated T-cells—blocking the IL-2 pathway and reducing immune response against the new kidney.

Each single-use vial contains 20 mg of basiliximab in solution. Doctors typically prescribe two doses: one within 2 hours after transplant and a second dose on day 4 post-transplant. This regimen offers effective rejection prevention without continuous monoclonal therapy.

Simulect works swiftly to suppress immune activity, thereby improving graft survival and reducing reliance on higher doses of standard immunosuppressants. It complements corticosteroids and calcineurin inhibitors like tacrolimus.

Healthcare providers administer Simulect via IV infusion in a hospital setting. Medical staff monitor patients closely during and after infusion, paying attention to potential infusion-related reactions.

Store unopened Simulect vials in the refrigerator at 2 °C to 8 °C, protected from light. Do not freeze. Once opened, no freezer storage—use per medical recommendation.